AgriLabs announces the United States Food and Drug Administration (FDA) approval of FluNix-D (flunixin meglumine) for use in lactating dairy cows. FluNix-D is a Non-Steroidal Inflammatory Drug (NSAID) that provides producers with a safe and effective support therapy for their dairy cows by reducing the fever and inflammation caused by Bovine Respiratory Disease (BRD) and endotoxemia.
FluNix-D may be administered intravenously or intramuscularly. The compound breaks down quickly in the animal's body and is cleared from the bloodstream via the urine. FluNix-D has a 36-hour milk withdrawal and four-day meat withdrawal in lactating dairy cows.
Flunixin Meglumine has been approved for horses for a number of years as therapy for inflammation, pyrexia and colic. It later was cleared for use in beef cattle and non-lactating dairy cows. It was just recently approved for use in lactating dairy cows.
The AgriLabs organization is made up of 23 independent veterinary product distributors operating 140 branch locations with approximately 650 sales representatives nationwide. AgriLabs' partnership structure and philosophy, together with a commitment to expeditious product development, provides a smooth, efficient system for manufacturers to transfer technology from the research laboratories to the animal health marketplace. Through technology transfer agreements with various manufacturers, AgriLabs has introduced a number of state-of-the-art products for the beef and dairy industries.